Healthpeak Reports Mixed Q4 & FY25 Results, Issues 2026 Guidance, and Progresses Senior Housing IPO
Summary
Healthpeak Properties reported mixed Q4 and full-year 2025 results, issued conservative 2026 guidance, and provided an update on its strategic initiatives, including the planned IPO of its senior housing portfolio and significant capital recycling activities.
Key Events
-
Q4 & Full Year 2025 Financial Performance
Reported Q4 2025 net income of $0.16 per share (up from $0.01 in Q4 2024) and Nareit FFO of $0.47 per share (up from $0.44). Full-year 2025 net income was $0.10 per share (down from $0.36 in FY 2024), with Nareit FFO of $1.81 per share (up from $1.61).
-
2026 Financial Guidance Issued
Provided 2026 guidance for diluted EPS of $0.34-$0.38, diluted Nareit FFO per share of $1.70-$1.74, and diluted FFO as Adjusted per share of $1.70-$1.74. Total Merger-Combined Same-Store Cash (Adjusted) NOI growth is projected at (1%) to 1%.
-
Janus Living IPO Progressing
Announced the formation and planned initial public offering (IPO) of Janus Living, Inc., a REIT dedicated to senior housing, with a confidential draft registration statement on Form S-11 submitted in December 2025. The IPO is expected to be completed in the first half of 2026.
-
Significant Capital Allocation Activities
Acquired a 1.4 million square foot campus in South San Francisco for $600 million and the remaining 46.5% joint venture interest in a 19-community senior housing portfolio for $314 million. The company plans $1 billion in asset sales, recapitalizations, and loan repayments in 2026, including $325 million in outpatient medical sales and a $68 million lab campus sale in early 2026.
Analysis
Healthpeak Properties announced mixed financial results for Q4 and full-year 2025, alongside a strategic update that includes the planned IPO of Janus Living, Inc., a senior housing REIT. While Q4 2025 saw a significant increase in net income and solid same-store NOI growth, the full-year 2025 net income declined. The 2026 guidance indicates a substantial increase in diluted EPS but a decrease in FFO and AFFO per share, with same-store NOI growth projected to be flat to slightly positive (0% to 1%). This low NOI guidance, particularly the negative outlook for the lab segment, suggests near-term operational challenges. However, the company is actively reshaping its portfolio through significant acquisitions in life science and senior housing, and a $1 billion capital recycling plan, aiming to unlock value and focus on higher-growth opportunities. The unencumbering of the senior housing portfolio is a positive balance sheet development.
At the time of this filing, DOC was trading at $17.00 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $12.2B. The 52-week trading range was $15.71 to $21.28. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.